Johnson & Johnson Enter Final Stage in COVID-19 Vaccine Trial with 60,000 Volunteers - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--ResearchAndMarkets.com published a new article on the vaccine industry "Johnson & Johnson Enter Final Stage in COVID-19 Vaccine Trial with 60,000 Volunteers"

Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the vaccine with 60,000 volunteers from around the world including participants from the US, South Africa, Brazil, Argentina, Columbia, and Chile. Johnson & Johnson's vaccine joins candidates developed by Moderna, Pfizer and BioNTech, and AstraZeneca and the University of Oxford in beginning the final stage of development.

The company has committed to manufacturing a billion doses of the vaccine on a not for profit basis if proven effective. In contrast to other vaccine candidates that require at least two doses, J&J's candidate requires just one dose. It also does not require freezing and can remain viable in its liquid form for several months. If the phase 3 trial is successful, both factors could have significant practical advantages for mass vaccination programs.

To see the full article and a list of related reports on the market, visit "Johnson & Johnson Enter Final Stage in COVID-19 Vaccine Trial with 60,000 Volunteers"

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.